Exploration of cardiac biomarkers to decline mortality in COVID-19 Patients

Abstract

COVID 19 disease is caused by SARS CoV-2 had been started from Wuhan, a city of China and affected hundreds of countries has no therapeutic agents known for the treatment. [2] The mortality rate of disease is high with the patients with pre-existing cardiovascular diseases. In some cases, COVID 19 is associated with induction of acute COVID 19 cardiovascular syndromes. The mortality risks of disease can be lessened by early detection of cardiovascular diseases and myocardial injuries by elevated level of cardiac biomarkers more specifically cardiac troponin I (cTnI) and B type natriuretic peptides (BNP)[4] and N terminal pro BNP NT pro BNP) [7]. Virus enters the cardiac cells by specific binding with spike proteins and caused increase destruction of myocardial cells and leading toward the release of specific cardiac troponin in the blood stream.